{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:52:03Z","timestamp":1789213923823,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AR062522"],"award-info":[{"award-number":["AR062522"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.bone.2016.09.013","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T13:03:55Z","timestamp":1474031035000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl\/+ osteogenesis imperfecta model"],"prefix":"10.1016","volume":"93","author":[{"given":"Joseph E.","family":"Perosky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma M.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terese N.","family":"Jenks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferrous S.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cortright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Sinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan C.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Caird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Kozloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2016.09.013_bb0005","article-title":"Osteogenesis imperfecta","author":"Forlino","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2016.09.013_bb0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bone.2016.09.013_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub3","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"7","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2016.09.013_bb0020","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.09.013_bb0030","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","article-title":"Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model","volume":"52","author":"McCarthy","year":"2002","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.09.013_bb0040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but has detrimental effects on osteoblasts and bone formation and decreases predicted material properties","volume":"24","author":"Uveges","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11832-011-0380-0","article-title":"Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates","volume":"6","author":"Nicolaou","year":"2012","journal-title":"J. Child. Orthop."},{"key":"10.1016\/j.bone.2016.09.013_bb0050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1210\/jc.2012-4195","article-title":"The paradox of prevention\u2014bilateral atypical subtrochanteric fractures due to bisphosphonates in osteogenesis imperfecta","volume":"98","author":"Manolopoulos","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.09.013_bb0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jbspin.2014.10.014","article-title":"Atypical fracture in a child with osteogenesis imperfecta","volume":"82","author":"Carpintero","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bone.2016.09.013_bb0060","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","article-title":"Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate","volume":"19","author":"Munns","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0722.2008.00529.x","article-title":"Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta","volume":"116","author":"Kamoun-Goldrat","year":"2008","journal-title":"Eur. J. Oral Sci."},{"key":"10.1016\/j.bone.2016.09.013_bb0070","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.09.013_bb0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2016.09.013_bb0080","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.09.013_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0095","first-page":"115","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71C","author":"Sinder","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.09.013_bb0100","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.09.013_bb0105","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap mice, a model of recessive osteogenesis imperfecta","author":"Grafe","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0110","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.bone.2016.09.013_bb0115","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0120","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.09.013_bb0130","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0135","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0140","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.09.013_bb0145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2016.09.013_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0155","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","author":"Recker","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.09.013_bb0165","doi-asserted-by":"crossref","first-page":"37923","DOI":"10.1074\/jbc.274.53.37923","article-title":"Use of the Cre\/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an a1(I) G349C substitution. Variability in phenotype in BrtlIV mice","volume":"274","author":"Forlino","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.09.013_bb0170","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1359\/JBMR.040111","article-title":"Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength","volume":"19","author":"Kozloff","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0175","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1359\/jbmr.080804","article-title":"Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors","volume":"23","author":"Uveges","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0180","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.09.013_bb0185","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.09.013_bb0190","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0195","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jbmr.5650100117","article-title":"Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate","volume":"10","author":"Cheng","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0200","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bone.2008.10.036","article-title":"Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo","volume":"44","author":"Kozloff","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.09.013_bb0205","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/jbmr.66","article-title":"Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo","volume":"25","author":"Kozloff","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0210","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bone.2009.07.078","article-title":"Beam hardening artifacts in micro-computed tomography scanning can be reduced by X-ray beam filtration and the resulting images can be used to accurately measure BMD","volume":"45","author":"Meganck","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.09.013_bb0215","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A threshold selection method from gray-level histograms","volume":"91","author":"Otsu","year":"1979","journal-title":"IEEE Trans Systems, Man, and Cybernetics"},{"key":"10.1016\/j.bone.2016.09.013_bb0220","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/JBMR.041234","article-title":"Genetic variation in structure-function relationships for the inbred mouse lumbar vertebral body","volume":"20","author":"Tommasini","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.09.013_bb0225","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/en.2013-1905","article-title":"Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26weeks of treatment with a sclerostin antibody","volume":"155","author":"Li","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2016.09.013_bb0230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bone.2014.07.031","article-title":"Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats","volume":"67","author":"Stolina","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.09.013_bb0235","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216302599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216302599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T18:40:31Z","timestamp":1565376031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216302599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":47,"alternative-id":["S8756328216302599"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.09.013","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl\/+ osteogenesis imperfecta model","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}